Delving into the Latest Updates on Colorado Prevention Center with Synapse

概览

关联

15

项与 Colorado Prevention Center 相关的临床试验

NCT06909565

/ Not yet recruiting临床4期IIT

Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.

开始日期2025-07-01

申办/合作机构

Duke University

[+3]

CTIS2023-508581-15-00

/ Recruiting临床3期

RandomizEd trial to DEtermine the efficacy and safety of FINErenone on morbidity and mortality among heart failure patients with left ventricular ejection fraction greater than or equal to 40% hospitalized due to an episode of acute decompensated Heart Failure (REDEFINE-HF) - 202301CPC

开始日期2024-10-08

申办/合作机构

Colorado Prevention Center

NCT06033950

/ Recruiting临床3期

A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).

开始日期2024-08-20

申办/合作机构

Colorado Prevention Center

[+2]

100 项与 Colorado Prevention Center 相关的临床结果

登录后查看更多信息

0 项与 Colorado Prevention Center 相关的专利（医药）

登录后查看更多信息

26

项与 Colorado Prevention Center 相关的文献（医药）

2025-05-01·Current Opinion in Cardiology

Advances in the management of obesity and heart failure: latest evidence from clinical trials

Review

作者: Harrington, Josephine L. ; Costa, Thomaz Alexandre

Purpose of reviewObesity is an important risk factor for heart failure with preserved ejection fraction (HFpEF). In patients who already have HFpEF, obesity contributes to high symptom burden and increased risk for heart failure (HF) hospitalization. This review examines the latest clinical trials assessing the efficacy of pharmacological interventions in the treatment of obesity-related HFpEF.Recent findingsRecent results from randomized clinical trials (RCTs) suggest that incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (e.g., semaglutide) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs (e.g., tirzepatide), can improve quality of life, exercise tolerance, and markers of HF severity while promoting weight loss in patients with obesity and HFpEF. Some evidence also suggests that these therapies may reduce risk for HF hospitalizations. Additionally, exploratory analyses of the nonsteroidal mineralocorticoid receptor antagonist finerenone has been associated with reduced cardiovascular mortality and total worsening HF events across all body mass index (BMI) levels, with greater benefits observed in patients with higher BMIs.SummaryAntiobesity medications such as semaglutide and tirzepatide may represent important treatment options for patients with obesity-related HFpEF. Additional evidence suggests that certain other HF medications may have increased efficacy in patients with obesity.

2022-10-04·JAMA

Telmisartan and Walking Performance in Peripheral Artery Disease

Article

作者: Beckman, Joshua A. ; Hess, Connie ; Bonaca, Marc P.

2020-03-03·Clinical Toxicology

In reply to Dr. Shah and Dr. Beuhler

Letter

作者: Gerardo, Charles J. ; Lavonas, Eric J. ; Anderson, Victoria E.

A polemic in response to Drs. Shah and Beuhler is given.Drs. Shah and Beuhler analyzed timing of Fab antivenom administration, and randomized clin. trial [RCT] from which this anal. was derived.However, authors believe that it is appropriate to incorporate evidence of benefit from early treatment into shared decision-making that includes patient-centered discussions of benefits, risk,and cost.

100 项与 Colorado Prevention Center 相关的药物交易

登录后查看更多信息

100 项与 Colorado Prevention Center 相关的转化医学

登录后查看更多信息